Pre-treatment With Azithromycin to Reduce Immunogenicity to Anti-Tumor Necrosis Factor-α Agents in Patients With Inflammatory Bowel Disease
Ontology highlight
ABSTRACT: This will be a randomized placebo-controlled trial in inflammatory bowel disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity
DISEASE(S): Biological Substance; Adverse Effect,Inflammatory Bowel Diseases,Intestinal Diseases,Necrosis
PROVIDER: 2752894 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA